Abstract
Lung adenocarcinoma (LUAD) is the most common histological subtype in non-small cell lung cancer, which is the malignant tumor with the highest mortality and morbidity in the world. Herein, ZNF280A, a member of the zinc finger protein family carrying two consecutive Cys2His2 zinc finger domains, was shown by us to act as a tumor driver in LUAD. The immunohistochemical analysis of ZNF280A in LUAD indicated its positive correlation with tumor grade, pathological stage and lymphatic metastasis, and negative relationship with patients’ survival. A loss-of-function study revealed the inhibition of LUAD development by ZNF280A in vitro and in vivo, whereas ZNF280A overexpression induced opposite effects. Statistical analysis of gene expression profiling in LUAD cells with or without ZNF280A knockdown identified EIF3C as a potential downstream of ZNF280A, which possesses similar regulatory effects on phenotypes of LUAD cells with ZNF280A. Moreover, downregulation of EIF3C in ZNF280A-overexpressed cells could attenuate neutralize the ZNF280A-induced promotion of LUAD. In summary, our study demonstrated that ZNF280A may promote the development of LUAD by regulating cell proliferation, apoptosis, cell cycle, and cell migration and probably via interacting EIF3C.
Highlights
Lung cancer is one of the malignant tumors that seriously threaten human health and life
The total incidence of non-small cell lung cancer (NSCLC) is ~80–85%, which can be mainly divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among which lung adenocarcinoma (LUAD) is the most common type of lung cancer[3,4]
The results of flow cytometry indicated the enhanced cell apoptosis of shZNF280A cells, which may be resulted from the G2 phase arrest of cell cycle (Fig. 2C, D)
Summary
Lung cancer is one of the malignant tumors that seriously threaten human health and life. According to the statistics of American Cancer Society, the incidence and mortality of lung cancer rank first among all malignant tumors[1,2]. Lung cancer can be divided into small cell lung cancer and non-small cell lung cancer (NSCLC). The total incidence of NSCLC is ~80–85%, which can be mainly divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among which lung adenocarcinoma (LUAD) is the most common type of lung cancer[3,4]. LUAD is surrounded by many blood vessels, prone to metastasis and invasion[5]. The early symptoms of lung cancer are not obvious, almost no discomfort, so the vast
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
